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Abstract
Background: Bone-marrow derived progenitor cells (PCs) may play a role in maintaining vascular health by actively 
repairing damaged endothelium. The purpose of this study in asymptomatic Old Order Amish men (n = 90) without hyper-
tension or diabetes was to determine if PC count, as determined by CD34+ cell count in peripheral blood, was associated 
with 10-year risk of cardiovascular disease (CVD) and measures of subclinical atherosclerosis.
Methods and Results: CD34+ cell count by ﬂ  uorescence-activated cell sorting, coronary artery calciﬁ  cation (CAC) by 
electron beam computed tomography, and CVD risk factors were obtained. Carotid intimal-medial thickness (CIMT) also 
was obtained in a subset of 57 men. After adjusting for 10-year CVD risk, CD34+ cell count was signiﬁ  cantly associated 
with CAC quantity ( p = 0.03) and CIMT ( p   0.0001). A 1-unit increase in natural-log transformed CD34+ cell count was 
associated with an estimated 55.2% decrease (95% CI: −77.8% to −9.3%) in CAC quantity and an estimated 14.3% decrease 
(95% CI: −20.1% to −8.1%) in CIMT.
Conclusions: Increased CD34+ cell count was associated with a decrease in extent of subclinical atherosclerosis in 
multiple arterial beds, independent of 10-year CVD risk. Further investigations of associations of CD34+ cell count 
with subclinical atherosclerosis in asymptomatic individuals could provide mechanistic insights into the atherosclerotic 
process.
Keywords: atherosclerosis, carotid arteries, coronary artery calciﬁ  cation, epidemiology, risk factors
Atherosclerosis is regarded as a localized response to injuries of the endothelial cell layer triggered by 
factors such as smoking, high blood pressure, and hypercholesterolemia.
1 Bone-marrow derived pro-
genitor cells (PCs), circulating in the peripheral blood and detectable because they express CD34 on 
their cell surface, may play a role in repairing injured endothelium.
2 A subset of these progenitor cells 
that express both CD34 and markers of endothelial lineage can home to sites of injury and differentiate 
into endothelial cells to help maintain the integrity of the endothelium.
A decreased number of circulating PCs has been shown to be significantly associated with 
cardiovascular disease (CVD) events after adjustment for CVD risk factors in selected samples and 
patients with angiographically documented coronary artery disease.
3,4 Decreased PC counts also have 
been associated with aging, increased number and level of coronary artery disease risk factors, and 
increased 10-year risk of coronary artery disease in clinical patients;
4 however, this ﬁ  nding has not been 
consistently conﬁ  rmed in healthy individuals.
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The purposes of the current study were to: 1) 
determine if the number of circulating PCs, as 
determined by the presence of the CD34 cell surface 
marker (i.e. CD34+ cell count), was associated with 
10-year CVD risk based on the Framingham CVD 
Risk Prediction Models;
6 and 2) determine if 
CD34+ cell counts were associated with the extent 
of subclinical atherosclerosis, after adjustment for 
10-year CVD risk. The study was conducted in 
asymptomatic Old Order Amish (OOA) men 
without hypertension or diabetes. Measures of 
subclinical atherosclerosis included quantity of 
coronary artery calciﬁ  cation (CAC) and common 
carotid artery intima-media thickness (CIMT).
Methods
Participants were recruited through the community-
based Amish Family Calciﬁ  cation Study (AFCS). 
The goals of the AFCS are to examine environmen-
tal and genetic risk factors for subclinical atheroscle-
rosis. The Amish tend to have a more homogenous 
lifestyle compared to other European Americans and 
are exposed to fewer confounding factors such as 
use of prescription medications and wide variation 
in diet, physical activity, education, and socioeco-
nomic status.
7 Participants were evaluated for tradi-
tional CVD risk factors at the Amish Research Clinic 
in Strasburg, Pennsylvania. An electron beam com-
puted tomography (EBCT) examination of the heart 
was conducted in Timonium, Maryland and high-
resolution B-mode ultrasound of the common carotid 
arteries was performed at the Amish Research Clinic. 
The Institutional Review Boards of the participating 
institutions approved the study. All participants gave 
informed consent.
CD34+ cell count and CAC measures were 
obtained in 103 AFCS men who were recruited 
from the OOA of Lancaster County, Pennsylvania 
between March 2002 and November 2005. Four 
men  74 years of age were excluded because the 
Framingham Risk Equations were developed in 
asymptomatic individuals who were ages 30 to 
74 years of age at baseline. Six men with a history 
of myocardial infarction or coronary surgery were 
excluded. One man with a history of hypertension 
and one man with a history of diabetes were excluded. 
Finally, one man with an extreme CAC quantity was 
excluded. This man, age 48 years, a non-smoker with 
cholesterol of 197 mg/dL, had a 10-year CVD risk 
of 6.6% and a CAC score of 3,007. The ﬁ  nal sample 
consisted of 90 men, ages 31–74 years with measures 
of CAC and CD34+ cell count. A subset (n = 57) of 
these men also had CIMT measurements through 
their participation in another study.
8 There was not 
a signiﬁ  cant difference in mean age, 10-year CVD 
risk, or natural log-transformed CAC quantity 
between men with and without CIMT measures.
Risk factor assessment
Height and weight were measured and body mass 
index (BMI; kg/m
2) was calculated. Standard enzy-
matic methods were used to measure total cholesterol, 
high-density lipoprotein (HDL)-cholesterol, and 
triglycerides after an overnight fast (Quest Diagnostics, 
Horsham, PA). Low-density lipoprotein (LDL)-
cholesterol was calculated with the Friedewald equa-
tion.
9 Systolic blood pressure (SBP; mmHg) and 
diastolic blood pressure (DBP; mmHg) were mea-
sured 3 times in the right arm with a standard sphyg-
momanometer and the average of the second and 
third measurements was used in these analyses. Self-
reported history of physician-diagnosed myocardial 
infarction, diabetes, or hypertension were also 
recorded. As well, self-reported history of coronary 
surgery or tobacco smoking were recorded.
The Framingham CVD Risk Prediction Model 
for males was used to estimate the 10-year 
probability of CVD (10-year CVD risk) that 
includes coronary heart disease, cerebrovascular 
disease, peripheral vascular disease, and heart 
failure based on age, SBP, treatment for hyperten-
sion, total cholesterol, HDL-cholesterol, current 
smoking status, and diabetes status.
6
CD34+ cell count
CD34+ cells were counted by a method modiﬁ  ed 
from Vasa and colleagues.
10 A fasting blood draw 
was collected in four milliliter Vacutainer
® tubes 
containing 5.4 mg of EDTA. The blood was diluted 
1:1 with sterile PBS. Peripheral blood mononuclear 
cells were isolated by centrifugation at 400 × g 
utilizing LSM
® lymphocyte separation media (ICN 
Biomedical) per the manufacturer’s instructions. 
The isolated mononuclear cells were washed twice 
with sterile PBS to remove platelets. After the sec-
ond wash, the mononuclear cell pellets were diluted 
with 900 μL of sterile PBS. Twenty microliters of 
each cell suspension, which had been diluted in 
20 ml of isoton, was treated with Beckman 
Coulter™ ZAP-OGLOBIN™ II red blood cell lytic 
reagent and the mononuclear cells were counted in 
a Beckman Coulter™ Particle Counter Z1 per the 55
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manufacturer’s instructions. For the study samples 
and controls, 1 × 10
6 cells were treated with FcR 
blocking reagent (Miltenyi Biotech). Labeling of 
CD34+ cells was accomplished by incubating with 
a ﬂ  uorescein isothiocyanate (FITC)-conjugated 
mouse anti-human CD34 monoclonal antibody (BD 
Biosciences) for 15 minutes at room temperature 
in the dark. Isotype controls were prepared with 
Mouse IgG1-FITC (BD Bioscience) for 15 minutes 
at room temperature in the dark. Excess primary 
antibody was removed with a PBS wash. We also 
attempted labeling FLK1+ cells as described by 
Laufs and coworkers
11 by treating with mouse anti-
FLK1 IgG monoclonal antibody (Santa Cruz) fol-
lowed by labeling with a goat anti-mouse IgG 
(whole molecule) R-Phycoerythrin conjugate 
(Sigma) for 15 minutes at room temperature in the 
dark and washing with PBS. However, subsequently 
we found that the epitope for the FLK1 antibody 
was intracellular and thus no binding occurred. 
Results from follow-up experiments to measure 
CD34+ cell count with and without the anti-FLK1 
antibody were identical, and thus only CK34+ cell 
count is reported. The study samples and controls 
were ﬁ  xed with 2% formalin/PBS solution and 
stored at 4 °C in the dark until they were counted 
in an Epics Elite ESP cell sorter (Beckman Coulter) 
at the University of Maryland School of Medicine 
Flow Cytometry Core Facility. Each analysis was 
gated over the lymphocyte area and included 
100,000 cytometric events. A correction control 
prepared with anti-CD3-FITC was used to deﬁ  ne 
cell populations or windows, which were positive 
and negative for ﬂ  uorescence. CD34+ cells were 
counted as cells that exhibited ﬂ  uorescence in 
the range of the positive anti-CD3-FITC controls. 
CD34+ cell count was expressed as the percentage 
of CD34+ cells/10
5 cytometric events.
Subclinical atherosclerosis
CAC presence and quantity were measured with 
EBCT (Imatron Inc., South San Francisco, California) 
using a standard protocol. All EBCT scans were 
scored for CAC by the same cardiologist (JAR) 
and reviewed by the same diagnostic radiologist 
(PFS). CAC was deﬁ  ned as a hyperattenuating 
focus  1.0 mm
2 in a coronary artery and having 
CT number  130 Hounsﬁ  eld Units. Quantity of 
CAC was deﬁ  ned as the CAC score in the four 
epicardial arteries using the method of Agatston 
and colleagues.
12
High resolution B-mode ultrasound was used 
to image the right and left common carotid arteries 
(CCAs). A single reader measured CIMT between 
the intima and media-adventitia interfaces of the 
far wall of the CCAs (the 1 cm segment proximal 
to the bifurcation) with an automated edge 
detection system.
13 The mean CIMT of this 1 cm 
segment was measured on two separate images of 
the left and the right CCA at the peak of the R wave 
on a simultaneous ECG tracing. The mean of these 
four measurements was used as the CIMT. Inter-
scan reproducibility for CIMT was 89% with this 
software and the inter-reader and intra-reader 
reproducibility was 97% and 98%, respectively.
Statistical analyses
All tests were 2-sided and a signiﬁ  cance level of 
p = 0.05 was used for all analyses. CD34+ cell count 
and CIMT were natural-log transformed to reduce 
skewness (i.e. ln(CD34+) and ln(CIMT), respec-
tively.) CAC score was natural log-transformed 
after adding one (i.e. ln(CAC score + 1)) to reduce 
skewness. Means and standard deviations (SD) for 
continuous variables, and frequencies and percent-
ages for discrete variables were calculated.
Because individuals in the same family par-
ticipated in the study, analyses were conducted 
accounting for the correlations among related 
individuals. These analyses utilized general-
ized estimating equations (GEE) with an exchange-
able working correlation structure in which all 
pair-wise correlations between participants from 
the same family were equal.
14 Although a complex 
pedigree structure characterized the Amish partici-
pants, families were deﬁ  ned on the basis of sibships 
for this analysis.
GEE models with the identity link function were 
ﬁ  t to assess the association between selected CVD 
risk factors and ln(CD34+). Each risk factor 
association, except age, was adjusted for age. 
A GEE model also was ﬁ  t to assess the association 
between ln(CD34+) and 10-year Framingham 
CVD risk. Finally, GEE models were ﬁ  t to assess 
the 10-year Framingham CVD risk-adjusted asso-
ciation between ln(CD34+) and each measure of 
subclinical atherosclerosis (i.e. ln(CAC score + 1) 
and ln(CIMT)).
Because each of the dependent variables in the 
GEE models were natural log transformed values, 
the parameter estimates were exponentiated to 
estimate the multiplicative difference in the level 56
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of the untransformed dependent variable associated 
with a speciﬁ  ed unit increase in the independent 
variable.
Results
The 90 men belonged to 77 sibships: 65 singletons; 
11 sibships of size 2; and 1 sibship of size 3. Char-
acteristics of study participants are presented in 
Table 1. Mean (SD) 10-year CVD risk was 8.4% 
(6.0%). Mean (SD) CD34+ cell count was 0.125% 
(0.06%). Forty-two percent of participants had 
detectable CAC, and the mean (SD) CAC score 
was 93.8 (282.5). Among the subset of 57 partici-
pants examined with carotid ultrasound, the mean 
(SD) CIMT was 0.62 mm (0.13 mm).
Associations between risk factors 
and CD34+ cell count
Age was marginally and inversely associated with 
ln(CD34+) ( p = 0.07) (Table 2). After adjusting for 
age, BMI ( p = 0.005) and smoking ( p = 0.02) were 
each signiﬁ  cantly and positively associated with 
ln(CD34+). Neither 10-year CVD risk nor any of 
the remaining age-adjusted selected risk factors were 
signiﬁ  cantly associated with ln(CD34+) (Table 2).
Associations between CD34+ 
and measures of subclinical 
atherosclerosis
Ln(CD34+) was significantly and inversely 
associated with ln(CAC+1) ( p = 0.01). In a mul-
tiple variable GEE model, 10-year CVD risk was 
significantly and positively associated while 
ln(CD34+) was signiﬁ  cantly and inversely associ-
ated with ln(CAC + 1) (Table 3). Based on this 
model, a 1-unit increase in ln(CD34+) was associ-
ated with an estimated 55.2% decrease in CAC 
quantity (95% CI: −77.8% to −9.3%; p = 0.03).
Ln(CD34+) was signiﬁ  cantly and inversely 
associated with ln(CIMT) ( p   0.0001). In a mul-
tiple variable GEE model (Table 3), 10-year CVD 
risk was signiﬁ  cantly and positively associated 
while ln(CD34+) was signiﬁ  cantly and inversely 
associated with ln(CIMT). Based on this model, a 
1-unit increase in ln(CD34+) was associated 
with a 14.3% decrease in CIMT (95% CI: −20.1% 
to −8.1%; p   0.0001).
There was no evidence for a signiﬁ  cant interac-
tion between 10-year CVD risk and ln(CD34+) in 
predicting either measure of subclinical atheroscle-
rosis (data not shown).
Discussion
Earlier insights into the role of PCs in athero-
sclerosis were obtained from experiments in 
atherosclerosis-prone apolipoprotein E (ApoE
–/–) 
deﬁ  cient mice. Periodic injection of bone mar-
row-derived cells into ApoE
–/– mice maintained 
on high-fat diets signiﬁ  cantly reduced the ath-
erosclerotic burden in these animals compared 
to ApoE
–/– mice who received sham injections.
15 
The injection of bone marrow-derived cells 
appeared to accelerate endothelial regeneration. 
Importantly, the infusion of bone marrow-derived 
cells from young donors (either ApoE
–/– or wild 
type) produced a much stronger effect than infus-
ing cells from aged, atherosclerotic donors 
(either ApoE
–/– or wild type).
15 These results 
suggested that older animals may be more prone 
to atherosclerosis due to impaired PC number or 
function.
Further insight into the role of progenitor cells 
in atherosclerosis in humans has focused on the 
use of cells that label both with CD34+, a marker 
of hematopoetic stem cells, and with KDR+, a 
marker of endothelial cell fate. In a study of  45 patients 
with angiographically documented coronary artery 
Table 1. Characteristics of 90 asymptomatic men from 
the Amish family calciﬁ  cation study.
Characteristic Mean ± SD or %
Age (years) 48.8 ± 10.0
Body mass index (kg/m
2) 25.8 ± 2.9
Cholesterol (mmol/L) 5.45 ± 1.00
HDL-cholesterol (mmol/L) 1.45 ± 0.35
LDL-cholesterol (mmol/L) 3.61 ± 0.95
Triglycerides (mmol/L) 0.84 ± 0.42
Systolic BP (mmHg) 115.2 ± 10.6
Diastolic BP (mmHg) 71.1 ± 8.0
Currently smoking 19%
10-year risk of CVD (%) 8.4 ± 6.0
CD34+ cell count (%) 0.125 ± 0.06
Presence of detectable CAC 42%
CAC Score 93.8 ± 282.5
CIMT (mm) (n = 57) 0.62 ± 0.13
Data are mean ± SD unless otherwise indicated.
Abbreviations: HDL-cholesterol, high-density lipoprotein-cholesterol; 
LDL-cholesterol, low-density lipoprotein-cholesterol; BP, blood pres-
sure; CVD, cardiovascular disease; CAC, coronary artery calciﬁ  cation; 
CIMT, common carotid intimal-medial thickness.57
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disease and 15 healthy volunteers, Vasa et al. found 
an inverse correlation between CD34+/KDR+ cell 
count and coronary artery disease risk factors.
10 In 
another study of 33 patients with acute coronary 
syndromes, 44 patients with stable coronary artery 
disease, and 43 control subjects, the investigators 
also found an inverse correlation between 
circulating CD34+/KDR+ cell count and age, 
hypertension, smoking, and family history of 
coronary artery disease.
3 Conversely, Heiss et al. 
did not find a significant difference in mean 
CD34+/KDR+ cells between younger (mean ± SD 
age of 25.0 ± 1.0 years) and older (mean ± SD age 
of 61.0 ± 2.0 years) healthy individuals.
16
In our study, we found, after adjusting for 10-year 
CVD risk, a signiﬁ  cant and inverse association 
between CD34+ cells and measures of subclinical 
atherosclerosis that are strong predictors of CVD 
risk. Additionally, we found a positive association 
between smoking and CD34+ cell counts. This 
apparently paradoxical positive association also 
was reported by Werner et al.
4 in 519 patients with 
angiographically conﬁ  rmed coronary artery disease 
and by Kunz et al.
17 in 122 patients undergoing 
cardiac catheterization. Nicotine has been shown 
to increase endotelial PC count.
18,19 Furthermore, 
brief exposure to second hand smoke in healthy 
non-smokers has been shown to immediately 
increase CD133+/KDR+ and CD34+/KDR+ 
counts; however, these cells exhibited a severe 
functional impairment.
20 OOA men typically 
smoke cigars and to our knowledge the effect of 
cigar smoke on PC count and function has not been 
investigated.
To further explore the signiﬁ  cant association 
between CD34+ cell counts and measures of sub-
clinical atherosclerosis in the current study, we 
stratiﬁ  ed the study group into men with 10-year 
CVD risk  10% and men with 10-year CVD 
risk  10%. CD34+ cell count was signiﬁ  cantly 
and inversely associated with CIMT and CAC 
quantity in each of the risk groups. Also, we 
included BMI as an additional covariate, along 
with 10-year CVD risk and CD34+ cell count, in 
prediction of CIMT and CAC quantity in the entire 
study group. Because of the association between 
BMI and ln(CD34+) (Table 2), the strength of the 
associations between ln(CD34+) and the subclini-
cal measures of atherosclerosis were attenuated. 
The inferences from these models that included 
BMI as a covariate, however, were similar to the 
models presented in Table 3.
As reviewed by Saremi and Arora,
21 quantity 
of CAC in symptomatic and asymptomatic adults 
predicts risk for future clinical events.
22–24 In 
a population-based study of 4,613 participants, 
CAC score predicted CVD events independently 
of traditional risk factors and C-reactive protein 
( p = 0.004), was superior to Framingham risk score 
in predicting events, and enhanced stratiﬁ  cation of 
those falling into the Framingham risk categories 
of low, intermediate, and high risk ( p   0.0001).
24 
Table 2. Risk factor associations with CD34+ cell count in 90 asymptomatic men from the Amish family 
calciﬁ  cation study.
Characteristic Unit increase 
in risk factor
Percent 
difference*
95% Conﬁ  dence 
Interval
P
Age 5 years −4.7   −21.9, 16.2 0.07
Body mass index 1 kg/m
2 4.8  1.9, 7.8 0.005
Cholesterol 0.25 mmol/L −0.3   −2.2, 1.6 0.75
HDL-cholesterol 0.125 mmol/L −0.7   −3.6, 2.4 0.67
LDL-cholesterol 0.25 mmol/L −0.1   −2.2, 2.0 0.89
Triglycerides 0.125 mmol/L −0.1   −2.4, 2.1 0.90
Systolic BP 10 mmHg 0.4   −7.4, 8.8 0.92
Diastolic BP 10 mmHg 6.1   −4.6, 17.9 0.27
Currently smoking Yes versus No 29.5   4.1,  61.0 0.02
10-year CVD risk 2% −1.9   −5.7, 2.0 0.33
Abbreviations: HDL-cholesterol, high-density lipoprotein-cholesterol; LDL-cholesterol, low-density lipoprotein-cholesterol; BP, blood pressure; 
CVD, cardiovascular disease; CAC, coronary artery calciﬁ  cation.
*Percent increase or decrease in CD34+ cell count associated with speciﬁ  ed unit increase in the risk factor. All risk factor associations, except 
age and 10-year CVD risk, were adjusted for age.58
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In the Atherosclerosis Risk in Communities Study, 
CIMT was a signiﬁ  cant predictor of future coro-
nary heart disease events after adjustment for 
traditional risk factors.
25
Limitations
Our study was conducted in asymptomatic OOA 
men with a relatively homogeneous social and 
cultural lifestyle. This limits our ability to general-
ize our ﬁ  ndings to other European American and 
ethnic populations with more diverse ways of life. 
We also can not generalize to women. In a previous 
study, there were signiﬁ  cant differences between 
OOA and other non-Hispanic white Americans in 
the distribution of many CVD risk factors.
7 Addi-
tionally, the power to detect associations between 
CD34+ cell count, 10-year CVD risk, and measures 
of subclinical atherosclerosis in this relatively 
small sample of men was modest.
There remains controversy as to the appropri-
ate method for deﬁ  ning the population of circulat-
ing cells, which constitute endothelial PCs, as 
these cells express different surface markers 
depending on their level of differentiation.
26 
Drawing from the method used by Hill et al. 
and Werner et al. we counted as PCs those cells 
that labeled with CD34, a marker of hematopo-
etic and endothelial lineage as well as prolifera-
tive capacity.
2,4 We did not, however, measure 
VEGFR2+ cells. VEGFR2+ cells are thought to 
represent a subpopulation of CD34+ cells that 
have further differentiated toward an endothelial 
cell lineage. Further work will be required to 
deﬁ  ne the subpopulation (if any) of CD34+ cells 
with the largest impact on endothelial repair and/
or atherosclerotic burden.
The CD34+ cell counts we observed are difﬁ  -
cult to compare with other studies as there are few 
published papers that report results for CD34+ 
cells alone and our study group was restricted to 
asymptomatic men. In one paper that parallels our 
approach to measuring CD34+ cells, Fadini et al. 
report mean CD34+ cell counts of ∼0.045% in a 
population of male and female ofﬁ  ce workers in 
Padua, Italy and marginal evidence for an asso-
ciation between CD34+ cell count and CIMT.
27 
Further studies are required to deﬁ  ne the distribu-
tion of CD34+ cell counts in various populations. 
The biology of PCs is complex. It was not pos-
sible with our cross-sectional study design to 
provide further insight into pathophysiological 
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mechanisms that underlie the associations found 
in this study.
Conclusion
Our ﬁ  ndings suggest that CD34+ cell counts may 
represent a subtle way of assessing subclinical 
atherosclerotic risk that is not apparent using 
global risk measures in healthy men. The com-
plex relationships between risk factors, PCs, and 
subclinical disease underscore the need for addi-
tional population-based studies to elucidate 
biological mechanisms involved in regulation 
of PCs.
Given the role of PCs in vascular homeostasis, 
a decline in circulating PC number may represent 
a biological tipping point, where intrinsic repair 
mechanisms can no longer effectively maintain 
vascular health. Individuals with decreased PCs 
may be at higher risk for events associated with 
subclinical atherosclerosis in multiple vascular 
beds and candidates for more aggressive risk factor 
modiﬁ  cation. Further understanding of the role of 
PCs in the pathogenesis of atherosclerosis may 
lead in the future to improved outcomes for 
individuals at risk for CVD.
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